Applied DNA Sciences Faces Potential Nasdaq Delisting Due to Bid Price Rule Non-Compliance

Reuters

2025/06/07

Applied DNA Sciences Faces Potential Nasdaq Delisting Due to Bid Price Rule Non-Compliance

Applied DNA Sciences Inc. has announced that it received a notice from Nasdaq indicating that the company no longer meets the $1.00 minimum bid price requirement necessary for continued listing on The Nasdaq Capital Market. This deficiency was identified after the company's common stock maintained a bid price below $1.00 per share for 32 consecutive business days from April 14 to May 29, 2025. In response, Applied DNA Sciences implemented a 1-for-15 reverse stock split to regain compliance. However, the company is not eligible for a compliance period due to recent reverse stock splits. As a result, its securities are at risk of being delisted unless a hearing request is granted by the Nasdaq Hearings Panel. The company has requested a hearing to defer any suspension or delisting actions, but there is no assurance that their request will be approved or that compliance will be regained.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied DNA Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-057222), on June 06, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2541867997"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541867997\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2541867997?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-07 02:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541867997","market":"nz","top_or_hot":-1,"title":"Applied DNA Sciences Faces Potential Nasdaq Delisting Due to Bid Price Rule Non-Compliance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Applied DNA Sciences Faces Potential Nasdaq Delisting Due to Bid Price Rule Non-Compliance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/APDN\">Applied DNA Sciences Inc</a>. has announced that it received a notice from Nasdaq indicating that the company no longer meets the $1.00 minimum bid price requirement necessary for continued listing on The Nasdaq Capital Market. This deficiency was identified after the company's common stock maintained a bid price below $1.00 per share for 32 consecutive business days from April 14 to May 29, 2025. In response, Applied DNA Sciences implemented a 1-for-15 reverse stock split to regain compliance. However, the company is not eligible for a compliance period due to recent reverse stock splits. As a result, its securities are at risk of being delisted unless a hearing request is granted by the Nasdaq Hearings Panel. The company has requested a hearing to defer any suspension or delisting actions, but there is no assurance that their request will be approved or that compliance will be regained.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied DNA Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-057222), on June 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Applied DNA Sciences Faces Potential Nasdaq Delisting Due to Bid Price Rule Non-Compliance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApplied DNA Sciences Faces Potential Nasdaq Delisting Due to Bid Price Rule Non-Compliance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-07 02:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Applied DNA Sciences Faces Potential Nasdaq Delisting Due to Bid Price Rule Non-Compliance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/APDN\">Applied DNA Sciences Inc</a>. has announced that it received a notice from Nasdaq indicating that the company no longer meets the $1.00 minimum bid price requirement necessary for continued listing on The Nasdaq Capital Market. This deficiency was identified after the company's common stock maintained a bid price below $1.00 per share for 32 consecutive business days from April 14 to May 29, 2025. In response, Applied DNA Sciences implemented a 1-for-15 reverse stock split to regain compliance. However, the company is not eligible for a compliance period due to recent reverse stock splits. As a result, its securities are at risk of being delisted unless a hearing request is granted by the Nasdaq Hearings Panel. The company has requested a hearing to defer any suspension or delisting actions, but there is no assurance that their request will be approved or that compliance will be regained.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied DNA Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-057222), on June 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDLcgzk2Z:1","article_id":"2541867997","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541867997","pubTimestamp":1749234557,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Applied DNA Sciences Inc. has announced that it received a notice from Nasdaq indicating that the company no longer meets the $1.00 minimum bid price requirement necessary for continued listing on The Nasdaq Capital Market. This deficiency was identified after the company's common stock maintained a bid price below $1.00 per share for 32 consecutive business days from April 14 to May 29, 2025. In response, Applied DNA Sciences implemented a 1-for-15 reverse stock split to regain compliance. However, the company is not eligible for a compliance period due to recent reverse stock splits. As a result, its securities are at risk of being delisted unless a hearing request is granted by the Nasdaq Hearings Panel. The company has requested a hearing to defer any suspension or delisting actions, but there is no assurance that their request will be approved or that compliance will be regained.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","BK4583":"猴痘概念","APDN":"Applied DNA Sciences"},"translate_title":"由于不遵守投标价格规则，Applied DNA Sciences可能面临纳斯达克退市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APDN":0.9},"content_text":"Applied DNA Sciences Faces Potential Nasdaq Delisting Due to Bid Price Rule Non-Compliance\n    \n\nApplied DNA Sciences Inc. has announced that it received a notice from Nasdaq indicating that the company no longer meets the $1.00 minimum bid price requirement necessary for continued listing on The Nasdaq Capital Market. This deficiency was identified after the company's common stock maintained a bid price below $1.00 per share for 32 consecutive business days from April 14 to May 29, 2025. In response, Applied DNA Sciences implemented a 1-for-15 reverse stock split to regain compliance. However, the company is not eligible for a compliance period due to recent reverse stock splits. As a result, its securities are at risk of being delisted unless a hearing request is granted by the Nasdaq Hearings Panel. The company has requested a hearing to defer any suspension or delisting actions, but there is no assurance that their request will be approved or that compliance will be regained.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied DNA Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-057222), on June 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"shareholding,policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}